Prosecution Insights
Last updated: November 20, 2026

Eric Tran, USPTO Patent Examiner

Listed by the USPTO as TRAN, ERIC

Tech Center 1600 • Art Units: 1629

This examiner grants 70% of resolved cases

Analysis

TRAN, ERIC is a USPTO patent examiner in Tech Center 1600 and Art Unit 1629. The record covers 119 resolved cases, a 69.7% allowance rate, and a median of 1028 days to allowance. The 19.4% interview lift provides a meaningful secondary signal and supports considering examiner interviews when a written response alone may not resolve the issues.

Listed companies include Mindset Pharma Inc., Endeavor Biomedicines Inc., and Pfizer Inc. Listed firms include Raphael Bellum PLLC, TROUTMAN PEPPER LOCKE LLP, and BROWN RUDNICK LLP. Practitioners can use the record to prepare application-specific amendments and arguments. The median timeline indicates that prosecution scheduling should account for more than a short examination cycle.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

69.7%
Allow Rate
+9.7% vs TC avg
161
Total Applications
+19.4%
Interview Lift
1028
Avg Prosecution Days
Based on 119 resolved cases, 2023–2026

Rejection Statute Breakdown

2.1%
§101 Eligibility
16.5%
§102 Novelty
30.4%
§103 Obviousness
33.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18823254 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof Non-Final OA NOVARTIS AG
19413522 INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Non-Final OA MINDSET PHARMA INC.
19189953 INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Non-Final OA MINDSET PHARMA INC.
18951832 Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer Non-Final OA MIRATI THERAPEUTICS, INC.
17781929 METHOD OF TREATMENT WITH KCNQ CHANNEL OPENERS Final Rejection Icahn School of Medicine at Mount Sinai
18416336 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS Non-Final OA Intervet Inc.
18780727 METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE Non-Final OA IMBRIA PHARMACEUTICALS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Eric Tran's allowance rate?

69.7% of resolved applications examined by Eric Tran were allowed (119 resolved cases), compared with 42.4% across Art Unit 1629 over the last five years.

Does an interview help with examiner Eric Tran?

This examiner's interview lift is +19.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Eric Tran take to allow a patent?

Applications allowed by Eric Tran took 1,028 days on average from filing to allowance.

Which art unit does examiner Eric Tran work in?

Eric Tran examines applications in Art Unit 1629 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month